BIOTON S.A. (0DTR) Share Price & Analysis
0DTR Stock Chart & Stats
- Day’s Range
- PLN 6.69 - PLN 6.69
- 52-Week Range
- PLN 6.69 - PLN 6.69
- Previous Close
- PLN 6.69
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- PLN 291.94M
- Enterprise Value
- PLN 406.03M
- Total Cash (Recent Filing)
- PLN 1.29M
- Total Debt (Recent Filing)
- PLN 67.30M
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Nov 10, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
A conservative leverage approach provides BIOTON with financial flexibility and reduces risk, supporting long-term sustainability.
Cash Flow Improvement
Improved cash flow generation enhances BIOTON's ability to reinvest in growth opportunities and maintain financial stability.
Revenue Growth
Strong revenue growth indicates increasing demand for BIOTON's products, enhancing its market position and potential for future expansion.
Bears Say
Low Operating Cash Flow
Low operating cash flow relative to net income suggests that BIOTON may struggle to cover its operational expenses, affecting financial health.
Negative Net Income
Negative net income reflects operational inefficiencies, which can hinder BIOTON's ability to invest in growth and return value to shareholders.
Declining Profit Margins
Decreasing profit margins indicate challenges in cost management and pricing power, potentially impacting long-term profitability.
0DTR FAQ
What was BIOTON S.A.’s price range in the past 12 months?
What is BIOTON S.A.’s market cap?
When is BIOTON S.A.’s upcoming earnings report date?
How were BIOTON S.A.’s earnings last quarter?
Is BIOTON S.A. overvalued?
Does BIOTON S.A. pay dividends?
What is BIOTON S.A.’s EPS estimate?
How many shares outstanding does BIOTON S.A. have?
What happened to BIOTON S.A.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BIOTON S.A.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
BIOTON S.A.
Bioton S.A. operates as a biotechnology company, engaged in the creation, production, distribution, and commercialization of a diverse array of pharmaceuticals, medicinal preparations, and active pharmaceutical ingredients. Its primary focus is on diabetes management, offering products such as recombinant human and conventional insulin, alongside oral anti-diabetic medications. The company's portfolio extends to include dietary supplements, blood glucose monitoring strips, and over-the-counter solutions for diabetics. Key insulin products include Gensulin N, Gensulin R, and Gensulin M30, available in vials and cartridges. Complementing these are advanced delivery and monitoring systems like the GensuPen 2 automatic injection device and the GensuCare glucometer for diabetes monitoring, alongside essential needles. Bioton S.A. distributes its offerings across numerous international markets, including Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. Beyond its core product activities, the company also undertakes advertising, advisory services, and general corporate management. Founded in 1989, its headquarters are situated in Ozarów Mazowiecki, Poland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeremy Launders
- Employees
- 361
- Website
- www.bioton.pl
- Address
- ul. Poznanska 12, Ozarów Mazowiecki, MZ, 05-850, PL
BIOTON S.A. (0DTR) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 2 | 4 |
| Technical Analysis | 1 | 0 | 0 |
| Moving Averages | 6 | 2 | 4 |
